Compare Abbott Laboratories (ABT) vs iShares Global Tech ETF (IXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs iShares Global Tech ETF — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while iShares Global Tech ETF trades at $136.45. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares Global Tech ETF pays none, and iShares Global Tech ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | IXN | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $149.74 |
52-Week Low | $82.57 | $92.92 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
IXN trades at $139.47, up 2.18% on the day, with a neutral technical signal overall. The ETF's technical indicators show mixed signals, with moving averages bearish and oscillators neutral. Recent news highlights its strong global tech exposure but notes high valuations and concentration risks. No recent financial statements or cash flow data are provided in the context for the current period.
The outlook for IXN is cautious due to stretched valuations and high expectations, with sentiment divided among analysts. Key risks include tech sector volatility and dependence on AI-driven growth. Investors should weigh the ETF's tech leadership against valuation concerns before making decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →
